Torrent Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
TORNTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Torrent Pharma reported strong FY25 results with standalone net sales rising ~13% to ₹9,485 cr and net profit jumping ~39% to ₹1,888 cr versus FY24. Consolidated net sales grew ~7% to ₹11,317 cr with net profit up ~15% to ₹1,911 cr. Operating margins expanded meaningfully from 34.3% to 37.2% on a standalone basis, helped by lower finance costs and an exceptional gain of ₹24 cr from a favourable NPPA overcharging settlement. The board recommended a final dividend of ₹6 per share, taking total FY25 dividend to ₹32 (640%) per share. The board also sought shareholder approval for a QIP of up to ₹5,000 cr and appointed Aman Mehta as Managing Director effective August 1, 2025. Auditor B S R & Co. LLP issued a clean (unmodified) opinion on both standalone and consolidated results.
Strong profit growth, margin expansion, and a hefty total dividend are positive for shareholders, though the QIP proposal of up to ₹5,000 cr could lead to equity dilution later. The clean audit and reduced debt (debt-equity improved to 0.34x) reinforce a healthy financial profile.